MedDataX Logo

Heart Rate Variability in White Coat Hypertension and Essential Hypertension

NCT ID: NCT00286884

Last Updated: 2006-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate heart rate variability in patients with white coat hypertension and patients with essential hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension White Coat Hypertension Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monitoring of heart rate variability

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 30-70 years
* office BP \>150/95 mmHg and 24-h ambulatory BP =/\>135/85 mmHg
* office BP \>150/95 mmHg and 24-h ambulatory BP \<135/85 mmHg
* office BP \<150/95 mmHg and 24-h ambulatory BP \<135/85 mmHg

Exclusion Criteria

* Clinical signs of disease of the heart, lungs, liver, kidneys, brain or endocrine organs
* neoplastic disease
* daily use of medicine
* alcohol abuse
* abnormal laboratory screening including blood-hemoglobin, blood-white cell count, plasma-creatinine, plasma-alanine-amino-transaminases, plasma-albumin, plasma-sodium, plasma-potassium, urinary glucose, urinary albumin; electrocardiogram
* pregnancy
* unwillingness to participate
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regional Hospital Holstebro

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Line B Madsen, MD

Role: PRINCIPAL_INVESTIGATOR

Regional Hospital Holstebro

Erling B Pedersen, MD

Role: STUDY_CHAIR

Regional Hospital Holstebro

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Medical Research, Holstebro Hospital

Holstebro, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MED.RES.HOS.2003.01.LBM

Identifier Type: -

Identifier Source: org_study_id